[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Weifang Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,66,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100648039","phase-3-normobaric-hyperoxia-with-extended-window-endovascular-therapy-for-acute-ischemic-stroke-opens-extend-100648039",false,"NCT07717216","Normobaric Hyperoxia With Extended-Window Endovascular Therapy for Acute Ischemic Stroke (OPENS-EXTEND)","Efficacy and Safety of Periprocedural Normobaric Hyperoxia With Endovascular Therapy for Acute Ischemic Stroke 6-24 Hours After Last Known Well: A Multicenter Randomized Sham-Controlled Phase 3 Trial","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Clinical signs and symptoms consistent with acute anterior-circulation ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 10 or greater at the time of randomization.\n3. Pre-stroke modified Rankin Scale (mRS) score of 0 or 1.\n4. Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 6 or greater on baseline non-contrast computed tomography or diffusion-weighted magnetic resonance imaging.\n5. Eligible for endovascular therapy according to current guideline-recommended clinical practice and the judgment of the treating stroke team and neurointerventional team.\n6. Randomization can be completed between 6 and 24 hours after the time the participant was last known well. Randomization and initiation of the study intervention must not cause an avoidable delay in endovascular therapy.\n7. Pre-procedural computed tomography angiography or magnetic resonance angiography confirms large-vessel occlusion consistent with the participant's neurological deficits, involving one of the following: internal carotid artery or M1 segment of the middle cerebral artery.\n8. Baseline level of consciousness score on item 1a of the NIHSS is 0 or 1.\n9. Written informed consent has been obtained from the participant or the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* General Exclusion Criteria\n\n  1. NIHSS score of less than 10 at the time of randomization; substantial neurological improvement such that the participant is no longer considered eligible for endovascular therapy; or imaging-confirmed spontaneous recanalization with no remaining treatable target-vessel occlusion.\n  2. Seizure at stroke onset when the current neurological deficits are considered primarily attributable to a postictal state, or when a reliable baseline NIHSS assessment cannot be obtained.\n  3. Active clinically significant bleeding or a bleeding diathesis that, in the judgment of the investigator or treating clinical team, makes endovascular therapy or participation in the study unsafe.\n  4. Platelet count below 100 × 10⁹\u002FL.\n  5. Clinically significant coagulation abnormality, anticoagulant exposure, or coagulation-factor deficiency that, according to the local standard of care at the participating center, makes the participant ineligible for endovascular therapy.\n  6. Severe or end-stage cardiac, hepatic, or renal dysfunction that is expected to substantially affect 90-day survival, functional outcome assessment, or the safety of study participation.\n  7. Persistent baseline blood glucose below 50 mg\u002FdL (2.78 mmol\u002FL) or above 400 mg\u002FdL (22.20 mmol\u002FL) after appropriate initial evaluation or correction.\n  8. Persistent systolic blood pressure above 185 mmHg or diastolic blood pressure above 110 mmHg despite appropriate antihypertensive treatment.\n  9. Life expectancy of less than 90 days because of a pre-existing disease or other underlying medical condition.\n  10. Known pregnancy.\n  11. Any of the following clinically significant respiratory diseases or conditions that, in the investigator's judgment, may make high-concentration oxygen therapy unsafe or interfere with reliable administration of the study intervention:chronic obstructive pulmonary disease; acute pulmonary infection; acute respiratory distress syndrome;clinically significant pleural effusion;chronic hypercapnic respiratory failure; another respiratory condition that may affect the safety of high-concentration oxygen therapy or the administration of the mask-based intervention.\n  12. Any of the following conditions before randomization: requirement for supplemental oxygen at a flow rate greater than 3 L\u002Fmin to maintain peripheral oxygen saturation above 94%;requirement for noninvasive ventilatory support because of respiratory failure; or requirement for invasive mechanical ventilation because of respiratory failure.\n  13. Persistent clinically significant vital-sign instability after initial treatment, including but not limited to: heart rate of 50 beats per minute or lower or 120 beats per minute or higher; peripheral oxygen saturation of 90% or lower;respiratory rate of 10 breaths per minute or lower or 30 breaths per minute or higher; or other unstable vital signs considered by the investigator to potentially compromise participant safety.\n  14. Active vomiting, a high risk of aspiration, or inability to tolerate the study mask, except for participants who require clinically indicated endotracheal intubation and mechanical ventilation.\n  15. Active gastrointestinal bleeding.\n  16. History of a severe adverse reaction to iodinated contrast media that cannot be adequately managed with premedication, an alternative contrast strategy, or other appropriate clinical measures and therefore precludes endovascular therapy.\n  17. Current participation in another interventional clinical trial that may interfere with the study intervention, safety assessment, or evaluation of study outcomes.\n  18. Any other disease, condition, or circumstance that, in the investigator's judgment, makes the participant unsuitable for the study or may interfere with study treatment, participant safety, or outcome assessment. The specific reason must be documented.\n* Imaging Exclusion Criteria\n\n  1. Evidence of intracranial hemorrhage on baseline computed tomography or magnetic resonance imaging, including but not limited to intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, or epidural hemorrhage.\n  2. Failure to meet the prespecified perfusion-mismatch imaging criteria, including an ischemic core volume of 70 mL or greater.\n  3. Pre-randomization computed tomography angiography or magnetic resonance angiography demonstrates abnormal vascular anatomy or excessive vascular tortuosity such that, in the judgment of the treating neurointerventionalist, the target vessel cannot be safely accessed with endovascular devices or endovascular therapy is technically infeasible.\n  4. Based on the medical history, computed tomography angiography, magnetic resonance angiography, or other imaging findings, any of the following is suspected to be the primary cause of the index stroke and is considered to make endovascular therapy inappropriate or unsafe: cerebral vasculitis; aortic dissection; cervical arterial dissection; or intracranial arterial dissection.\n  5. Intracranial vascular occlusions involving multiple independent vascular territories, bilateral anterior-circulation infarction, or simultaneous anterior- and posterior-circulation infarction.\n\n     A tandem lesion consisting of cervical internal carotid artery occlusion together with an intracranial large-vessel occlusion in the same vascular territory will not be automatically excluded if the treating neurointerventionalist considers endovascular therapy appropriate.\n  6. Confirmed moyamoya disease or moyamoya syndrome.\n  7. Substantial cerebral edema, mass effect, or midline shift on baseline computed tomography or magnetic resonance imaging.\n  8. Intracranial neoplasm that may affect the 90-day functional outcome, increase the risk of hemorrhage, or interfere with study assessment. A small, asymptomatic meningioma may be permitted at the investigator's discretion.","ALL","18 Years",{"count":19,"type":20},314,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Although endovascular therapy (EVT) has substantially improved recanalization rates and extended the treatment window for acute ischemic stroke, fewer than half of patients achieve functional independence despite successful reperfusion. Growth of the ischemic core before reperfusion and ischemia-reperfusion injury after recanalization may contribute to unfavorable outcomes. Therefore, an adjunctive neuroprotective strategy that preserves the ischemic penumbra before and during EVT may further improve clinical outcomes.\n\nNormobaric hyperoxia (NBO) is a noninvasive and readily available treatment that delivers high-concentration oxygen at normal atmospheric pressure. By increasing oxygen delivery to hypoperfused but potentially salvageable brain tissue, NBO may delay infarct growth, preserve the blood-brain barrier, and reduce reperfusion injury. Previous preclinical studies and early clinical trials have suggested that NBO may provide neuroprotection without increasing oxidative stress or other major safety risks. The previous OPENS-1 and OPENS-2 trials showed that periprocedural NBO combined with EVT reduced infarct volume and improved 90-day functional outcomes in patients treated within 6 hours after stroke onset. In addition, a preliminary two-center study involving 120 patients treated 6-24 hours after onset suggested greater early neurological improvement and a potentially favorable 90-day functional outcome with NBO plus EVT compared with EVT alone.\n\nOPENS-EXTEND is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of periprocedural NBO as an adjunct to EVT in patients with acute ischemic stroke caused by anterior-circulation large-vessel occlusion who present 6-24 hours after symptom onset or last known well and have imaging evidence of salvageable ischemic brain tissue. Participants will be randomly assigned to receive either EVT combined with NBO or EVT with standard medical management alone. The primary hypothesis is that adjunctive NBO will improve functional outcomes at 90 days without increasing safety risks.",[26,27,28,29],"Stroke, Acute","Neuroprotection","Normobaric Hyperoxia","Endovascular Treatment","NOT_YET_RECRUITING","2026-07-17",{"date":33,"type":34},"2026-07-21","ACTUAL",{"date":36,"type":20},"2026-09-01",{"date":38,"type":20},"2029-09-01",{"name":40,"class":41},"Weifang Medical University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100622097","phase-3-hr-mri-directed-tirofiban-therapy-for-late-window-acute-ischemic-stroke-tian-100622097","NCT07379190","HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Acute ischemic stroke (AIS) in the anterior intracranial circulation (internal carotid artery system) confirmed by clinical symptoms and imaging examinations;\n3. Time from symptom onset or last known normal state to randomization: \\> 24 hours and ≤ 7 days;\n4. Stroke subtype confirmed as intracranial large artery atherosclerosis (ICAS) by high-resolution vessel wall imaging (HR-VWI) according to the TOAST classification, with cardiogenic embolism and other etiologies excluded;\n5. Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-20 at the time of randomization;\n6. Signed informed consent form obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis)；\n2. Intracranial hemorrhage confirmed by computed tomography (CT)；\n3. Definite or suspected cardiogenic embolism；\n4. History of atrial fibrillation or current electrocardiogram indicating atrial fibrillation；\n5. Acute ischemic stroke caused by other etiologies, such as Moyamoya disease, arterial dissection, arteritis, etc；\n6. Imaging examinations indicating that the area of the current cerebral infarction exceeds 1\u002F2 of the area of a single cerebral lobe;\n7. Known contraindications to antiplatelet therapy, including hematochezia, gastrointestinal bleeding, or any other hemorrhagic disorders;\n8. History of hypersensitivity to aspirin;\n9. Definite indication for anticoagulant therapy expected during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state, etc.);\n10. Complicated with malignant tumors, chronic hemodialysis, severe renal insufficiency (glomerular filtration rate \\[GFR\\] \\\u003C 30 ml\u002Fmin or serum creatinine \\[Cr\\] \\> 220 μmol\u002FL (2.5 mg\u002Fdl)), or severe hepatic insufficiency (serum alanine aminotransferase \\[ALT\\] \\> 2 times the upper limit of normal \\[ULN\\], or serum aspartate aminotransferase \\[AST\\] \\> 2 times the ULN);\n11. Severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification Class III or IV);\n12. Complicated with severe non-cardiovascular comorbidities, with an estimated survival time \\\u003C 6 months;\n13. Concurrent new cerebral infarction in both anterior and posterior circulations;\n14. Inability to complete the follow-up procedures;\n15. Presence of other known neurological disorders that may complicate the follow-up;\n16. Concurrent participation in other therapeutic clinical trials with incomplete treatment and follow-up;\n17. Other conditions that the investigators consider inappropriate for enrollment in this study.",{"count":50,"type":20},458,[23],"This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.",[26,54,55],"Stroke, Ischemic","Cerebral Infarction","RECRUITING","2026-06-24",{"date":59,"type":34},"2026-06-25",{"date":61,"type":34},"2026-06-22",{"date":63,"type":20},"2029-05-01",{"name":40,"class":41},1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100635879","the-effects-of-exercise-snacks-on-endothelial-function-and-body-composition-in-overweight-individuals-100635879","NCT07558421","The Effects of Exercise Snacks on Endothelial Function and Body Composition in Overweight Individuals","Inclusion Criteria:\n\n1. Age: 18-35 years old (male, female);\n2. Clear consciousness, stable vital signs;\n3. Able to understand and follow simple instructions;\n4. No regular exercise for at least 3 months;\n5. BMI ≥ 24 kg\u002Fm2.\n\nExclusion Criteria:\n\n1. There are other serious diseases, such as tumors;\n2. There are other neurological diseases;\n3. There are serious diseases that simultaneously affect the heart, liver, kidneys, endocrine system or hematopoietic system;\n4. There is a history of alcohol or drug abuse;\n5. Participated in other clinical trials that might affect the results of this study;\n6. There are other neurological or musculoskeletal diseases, with pain worsening with exercise;\n7. It is forbidden to engage in physical training.\n8. Within the past 3 months, there have been acute cardiovascular events such as acute myocardial infarction,unstable angina pectoris, severe arrhythmia, acute heart failure, etc.；\n9. Uncontrolled hypertension；\n10. Severe pulmonary diseases, such as uncontrolled asthma, acute exacerbation of chronic obstructive pulmonary disease, interstitial lung disease with significant exercise limitation；\n11. Severe joint and bone diseases, acute soft tissue injuries, fractures that have not healed, etc., making it impossible to complete the prescribed exercise load；\n12. Presence of bleeding tendencies, coagulation dysfunction, or within the past 1 month, there has been major bleeding or a history of surgery；\n13. The investigator judges that there are any other situations that may affect the safety of the subjects or the results of the trial.","35 Years",{"count":74,"type":20},60,[76],"NA","This randomized controlled trial investigates the effects of two types of stair-climbing exercise snacks versus moderate-intensity continuous training on vascular health, body composition, and blood lipids in overweight or obese adults. Participants will be assigned to one of four groups for 6-8 weeks. The control group receives no exercise intervention. Primary outcomes include endothelial function (ultrasound), body composition (InBody), and lipid profile (blood test).",[79,80],"Overweight","Obesity","2026-04-22",{"date":83,"type":34},"2026-04-30",{"date":85,"type":20},"2026-04-16",{"date":87,"type":20},"2026-07-20",{"name":40,"class":41},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":96,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100587011","the-effectiveness-of-a-virtual-reality-based-multisensory-intervention-100587011","NCT06922838","The Effectiveness of a Virtual Reality-based Multisensory Intervention","Effectiveness of a Virtual Reality-based Multisensory Intervention for Postoperative Recovery in Patients Receiving Gynecological Surgery","Inclusion Criteria: 1) significant postoperative pain response (VAS score over 4); 2) age greater than 18 years and volunteered to participate in this study.\n\nExclusion Criteria: 1) patients with psychosomatic disorders such as delirium, schizophrenia, and bipolar disorder; 2) patients with epilepsy, motion sickness, lightsensitivity, or other neurological diseases may have difficulty wearing the VR headset; 3) patients have severe heart, liver, kidney, blood, digestive, and nervous diseases.","FEMALE","75 Years",{"count":99,"type":20},100,[76],"This study explores the effectiveness of a virtual reality-based multisensory intervention for postoperative recovery in patients receiving gynecological surgery.",[103],"Gynecological Disease",[105,106,107,108],"Pain management","Virtual reality","Gynecology","Postoperative recovery","2025-04-09",{"date":111,"type":34},"2025-04-11",{"date":113,"type":20},"2025-04-06",{"date":115,"type":20},"2025-08-01",{"name":40,"class":41},""]